Despite advances and progress seen in breast cancer in recent years, current data highlights that breast cancer incidence and mortality remain the highest for cancer in women, with an estimated 2.1 million new cases and 626,679 deaths in 2018. This trend is only going to accelerate in the next 20 years, with a disproportionate number of cases and deaths expected to occur in low-resource settings.
To tackle the growing breast cancer burden, it is critical that improvements are made in
The breast cancer series aims to highlight these key issues and foster focused discussions amongst UICC members and renowned experts on key actions needed to reduce the global breast cancer burden.
The programme is supported by Pfizer as a founding partner, as well as Daiichi Sankyo, the US National Cancer Institute Center for Global Health, the Breast Health Global Initiative and is connected to the Breast Cancer Initiative 2.5.